JPRN-UMIN000027382已完成2 期
Phase II randomized clinical trial to investigate efficacy of zoledronic acid for the patients with metastatic or advanced breast cancer - Randomized clinical trial to investigate efficacy of zoledronic acid for the patients with metastatic or advanced breast cancer
Kyushu Breast Cancer Study Group (KBC-SG)0 个研究点目标入组 90 人开始时间: 2017年5月19日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 90
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- Female
入选标准
- 未提供
排除标准
- •1) There is any infection or complication of teeth 2) History of allergy by zoledronic acud 3) Patients with osteoporosis who needs therapy by bisphosphonates
研究者
相似试验
已完成
2 期
A randomized phase 2 trial which investigate the most effective administration method of antithrombin (AT) products in patients with disseminated intravascular coagulation (DIC) associated with sepsis during treatment for advanced pancreatic and biliary cancer.advanced hepatobiliary and pancreatic cancer patientsJPRN-UMIN000015105Osaka Medical Center for Cancer and Cardiovascular Diseases Department of Medical Oncology40
暂停
2 期
A phase II randomized clinical trial to determine the effectiveness of goreisan and saireito for lower limb lymphedema in women treated for gynecologic cancerower Limb LymphedemaLymphedemaD008209JPRN-jRCT1041190019Kajiyama Hiroaki40
已完成
2 期
Efficacy of a new COVID-19 treatmentPACTR202006899597082Malagasy government60
进行中（未招募）
1 期
Evaluating the effect of Loratadine associated with Rapamune in Lymphagioleiomyomatosis (LAM).EFFECT OF LORATADINE ON LYMPHANGIOLEIOMYOMATOSISMedDRA version: 21.0Level: PTClassification code 10049459Term: LymphangioleiomyomatosisSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2020-000702-29-ESIDIBELL (Institut d’Investigació Biomédica de Bellvitge)62
已完成
不适用
Phase II randomized clinical trial for the purpose of examining the protective efficacy of the non-alcoholic fatty liver development by pancrelipase preparation being given for pancreatic cancer patients who underwent pancreaticoduodenectomy or total pancreatectomy.To assume the decreased rate of post-operative non-alcoholic fatty liver incidence in pancreatic cancer patients with the prophylactic administration of the pancrelipase preparation.JPRN-UMIN000019817Department of Surgery, Kansai Medical University80